1bnt

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1bnt" size="450" color="white" frame="true" align="right" spinBox="true" caption="1bnt, resolution 2.15&Aring;" /> '''CARBONIC ANHYDRASE ...)
Line 1: Line 1:
-
[[Image:1bnt.gif|left|200px]]<br />
+
[[Image:1bnt.gif|left|200px]]<br /><applet load="1bnt" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1bnt" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1bnt, resolution 2.15&Aring;" />
caption="1bnt, resolution 2.15&Aring;" />
'''CARBONIC ANHYDRASE II INHIBITOR'''<br />
'''CARBONIC ANHYDRASE II INHIBITOR'''<br />
==Overview==
==Overview==
-
X-ray crystal structures of carbonic anhydrase II (CAII) complexed with, sulfonamide inhibitors illuminate the structural determinants of high, affinity binding in the nanomolar regime. The primary binding interaction, is the coordination of a primary sulfonamide group to the active site zinc, ion. Secondary interactions fine-tune tight binding in regions of the, active site cavity &gt;5 A away from zinc, and this work highlights three, such features: (1) advantageous conformational restraints of a bicyclic, thienothiazene-6-sulfonamide-1,1-dioxide inhibitor skeleton in comparison, with a monocyclic 2,5-thiophenedisulfonamide skeleton; (2) optimal, substituents attached to a secondary sulfonamide group targeted to, interact with hydrophobic patches defined by Phe131, Leu198, and Pro202;, and (3) optimal stereochemistry and configuration at the C-4 position of, bicyclic thienothiazene-6-sulfonamides; the C-4 substituent can interact, with His64, the catalytic proton shuttle. Structure-activity relationships, rationalize affinity trends observed during the development of, brinzolamide (Azopt), the newest carbonic anhydrase inhibitor approved for, the treatment of glaucoma.
+
X-ray crystal structures of carbonic anhydrase II (CAII) complexed with sulfonamide inhibitors illuminate the structural determinants of high affinity binding in the nanomolar regime. The primary binding interaction is the coordination of a primary sulfonamide group to the active site zinc ion. Secondary interactions fine-tune tight binding in regions of the active site cavity &gt;5 A away from zinc, and this work highlights three such features: (1) advantageous conformational restraints of a bicyclic thienothiazene-6-sulfonamide-1,1-dioxide inhibitor skeleton in comparison with a monocyclic 2,5-thiophenedisulfonamide skeleton; (2) optimal substituents attached to a secondary sulfonamide group targeted to interact with hydrophobic patches defined by Phe131, Leu198, and Pro202; and (3) optimal stereochemistry and configuration at the C-4 position of bicyclic thienothiazene-6-sulfonamides; the C-4 substituent can interact with His64, the catalytic proton shuttle. Structure-activity relationships rationalize affinity trends observed during the development of brinzolamide (Azopt), the newest carbonic anhydrase inhibitor approved for the treatment of glaucoma.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
1BNT is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with HG, ZN and AL2 as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Carbonate_dehydratase Carbonate dehydratase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.2.1.1 4.2.1.1] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1BNT OCA].
+
1BNT is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=HG:'>HG</scene>, <scene name='pdbligand=ZN:'>ZN</scene> and <scene name='pdbligand=AL2:'>AL2</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Carbonate_dehydratase Carbonate dehydratase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=4.2.1.1 4.2.1.1] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1BNT OCA].
==Reference==
==Reference==
Line 18: Line 17:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Boriack-Sjodin, P.A.]]
+
[[Category: Boriack-Sjodin, P A.]]
-
[[Category: Christianson, D.W.]]
+
[[Category: Christianson, D W.]]
[[Category: Zeitlin, S.]]
[[Category: Zeitlin, S.]]
[[Category: AL2]]
[[Category: AL2]]
Line 28: Line 27:
[[Category: zinc enzyme]]
[[Category: zinc enzyme]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 16:12:41 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 11:57:11 2008''

Revision as of 09:57, 21 February 2008


1bnt, resolution 2.15Å

Drag the structure with the mouse to rotate

CARBONIC ANHYDRASE II INHIBITOR

Contents

Overview

X-ray crystal structures of carbonic anhydrase II (CAII) complexed with sulfonamide inhibitors illuminate the structural determinants of high affinity binding in the nanomolar regime. The primary binding interaction is the coordination of a primary sulfonamide group to the active site zinc ion. Secondary interactions fine-tune tight binding in regions of the active site cavity >5 A away from zinc, and this work highlights three such features: (1) advantageous conformational restraints of a bicyclic thienothiazene-6-sulfonamide-1,1-dioxide inhibitor skeleton in comparison with a monocyclic 2,5-thiophenedisulfonamide skeleton; (2) optimal substituents attached to a secondary sulfonamide group targeted to interact with hydrophobic patches defined by Phe131, Leu198, and Pro202; and (3) optimal stereochemistry and configuration at the C-4 position of bicyclic thienothiazene-6-sulfonamides; the C-4 substituent can interact with His64, the catalytic proton shuttle. Structure-activity relationships rationalize affinity trends observed during the development of brinzolamide (Azopt), the newest carbonic anhydrase inhibitor approved for the treatment of glaucoma.

Disease

Known disease associated with this structure: Osteopetrosis, autosomal recessive 3, with renal tubular acidosis OMIM:[611492]

About this Structure

1BNT is a Single protein structure of sequence from Homo sapiens with , and as ligands. Active as Carbonate dehydratase, with EC number 4.2.1.1 Full crystallographic information is available from OCA.

Reference

Structural analysis of inhibitor binding to human carbonic anhydrase II., Boriack-Sjodin PA, Zeitlin S, Chen HH, Crenshaw L, Gross S, Dantanarayana A, Delgado P, May JA, Dean T, Christianson DW, Protein Sci. 1998 Dec;7(12):2483-9. PMID:9865942

Page seeded by OCA on Thu Feb 21 11:57:11 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools